written on 28.04.2014

Irreconcilable differences? Allergan investors wary of suitor Valeant's cost-slashing style


Last week, Valeant CEO J. Michael Pearson seemed confident he could woo Allergan shareholders with his $46 billion bid–even after the California-based company's board swallowed a poison pill. But now, some of Allergan's largest shareholders are begging to differ. And that could threaten Pearson's quest to bag his latest target.